At the end of his second term in 2018, Strange stepped down as president of MDI Biological Laboratory to focus his efforts on growing Revidia Therapeutics and advancing their drug candidate into clincial trials. Strange is currently Professor of Anesthesiology at Vanderbilt University School of Medicine and Principal Scientist at Revidia Therapeutics.
